Myocardial perfusion imaging using positron emission tomography (PET) has several advantages over single photon emission computed tomography (SPECT). The recent advances in SPECT technology have shown promise, but there is still a large need for PET in the clinical management of coronary artery disease (CAD). Especially, absolute quantification of myocardial blood flow (MBF) using PET is extremely important. In spite of considerable advances in the diagnosis of CAD, novel PET radiopharmaceuticals remain necessary for the diagnosis of CAD because clinical use of current cardiac radiotracers is limited by their physical characteristics, such as decay mode, emission energy, and half-life. Thus, the use of a radioisotope that has proper characteristics and a proper half-life to develop myocardial perfusion agents could overcome these limitations. In this review, the current state of cardiac PET and a general overview of novel 18
Introduction
Single photon emission computed tomography (SPECT) has played an important role in assessing myocardial blood flow (MBF) and in diagnosing CAD since the 1980s [1, 2] . However, the technical limitations of SPECT imaging using 99m Tc-labeled radiotracers, such as the difficulty of photon attenuation correction and uptake of radiotracers in the liver, may limit the diagnostic accuracy of SPECT [3] . PET has a number of technical advantages over SPECT, such as higher spatial resolution, a standardized method for the correction of photon attenuation, and quantitative measurement of MBF [4] . However, the PET radioisotopes which are currently used in diagnosis of CAD have a short physical half-life ([ This means that these radioisotopes need an on-site cyclotron or generator for their widespread use in the clinic [5] . Thus, the use of radioisotopes that have proper physical characteristics and a proper half-life to label myocardial imaging agents (MIA) could overcome these limitations. Previously, radiosynthesis and in vivo characterization of 18 F-labeled phosphonium cations were reported and discussed [6] . In this review, the current state of cardiac PET and a general overview of novel 18 F (including phosphonium cations) or 68 Galabeled radiotracers are provided. 18 F (half-life, 109.8 min; β + , 97%) or 68 Ga (half-life, 67.7 min; β + , 88%) are popular radioisotopes used to develop small molecule radiopharmaceuticals for PET due to favorable decay characteristics. Furthermore, clinical perspectives of cardiac PET are discussed.
The Current State of Cardiac PET
There is a large need for PET in the management of CAD due to its advantages over SPECT, such as superior image quality, less radiation dose, and absolute quantification of MBF. In a recent report, the excellent image quality with PET was actually associated with superior diagnostic accuracy in the detection of functionally significant CAD, as compared to that of not only SPECT but also coronary CT [7] . Both sensitivity and specificity of PET were well above 80%, in contrast to SPECT with suboptimal sensitivity and coronary CT with suboptimal specificity. Absolute quantification of MBF by myocardial perfusion PET has also shown promise in the clinical management of CAD. PET-measured absolute MBF parameters have shown superior diagnostic values compared to relative analysis of a perfusion defect [8, 9] . PET-measured MBF parameters also show prognostic values. Even in the subgroup of patients with abnormal perfusion (summed stress score, ≥ 4), coronary flow reserve (CFR, < 2.0) measured by [ 13 N]NH 3 PET was still predictive of future cardiac events [10] . PET-measured CFR was predictive of cardiac events, being independent from angiographic severity of epicardial CAD. Bypass surgery, in comparison with percutaneous coronary intervention, was related to a better prognosis in patients with CFR < 2.0 [11] . PET-measured CFR is considered to reflect not only focal significant stenosis but also underlying diffuse atherosclerosis, and it may help to decide on the optimal treatment strategy in CAD patients [11, 12] .
However, current myocardial perfusion PET radiotracers generally require an on-site cyclotron (except for 82 Rb) mainly due to their short half-lives. This results in limited distribution and clinical utilization of myocardial perfusion PET. Recent studies suggest that cadmium-zinc-telluride (CZT) SPECT may be a substitute for myocardial perfusion PET. It showed improved image quality as compared to conventional SPECT, improved diagnostic accuracy, less radiation exposure, and even quantification of MBF [13] [14] [15] [16] [17] . Although the measurement of MBF using CZT SPECT is in progress, the generally lower extraction fraction of 99m Tc-labeled agents may increase image noise and is suboptimal for accurate calculation of MBF [18] . It was recently shown that the resting MBF measured by CZT SPECT was comparable to that measured by [ 13 N]NH 3 PET, but stress MBF and CFR were significantly underestimated [19] . The obtuse correlation curve between MBF values measured by CZT SPECT and [ 13 N]NH 3 PET reflects the suboptimal non-linear extraction fraction of myocardial SPECT agents, which is highlighted during vasodilator stress. With respect to the fact that the mainstay of functional assessment of CAD is based on stress perfusion, the concerns related to the low extraction fraction of SPECT agents ( 99m Tc-labeled agents) raise questions about its clinical reliability.
Thus, an 18 F-labeled myocardial perfusion agent was developed, and it was expected to provide comparable or even superior image quality compared to current PET agents, as well as wide availability due to its longer half-life [20] [21] [22] [23] [24] and obese [25] patients showed superior diagnostic accuracy and met the non-inferiority threshold for specificity, the application of 18 F-flurpiridaz has not yet become a clinical reality.
Novel

F-Labeled Myocardial Perfusion Agents
Mitochondria play an important role in cell life and cell death. Especially, mitochondria constitute 20 to 30% of the myocardial intracellular volume as powerhouse [23] . Thus, unique protein or characteristics of mitochondria are a major target for developing of PET myocardial imaging agents.
First target of mitochondria for developing of PET myocardial perfusion agents is mitochondrial complex I (MC-1). MC-1 is the first enzyme of four electron transport complexes in the inner mitochondrial membrane. [23, 26, 27] . Rotenone derivatives showed higher uptake than 99m Tc-MIBI in an isolated rabbit heart. However, the mechanism of rotenone derivatives in myocytes had not been fully cleared and a large amount of rotenone derivatives was retained nonspecifically in the mitochondrial membrane. [ 18 F]flurpiridaz represented high quality of myocardium image and had ability to visualize and quantify cardiac defects in different animal models including humans. However, the phase III trial failed due to already mentioned diagnostic accuracy.
Second target is the mitochondrial membrane potential (MP) in cardiomyocytes. The MP of cardiomyocytes is higher than that of normal epithelial cells, and loss of MP is a signal for cell death caused by myocardial ischemia [28, 29] . Quaternary ammonium and phosphonium cations accumulate in mitochondria of cardiomyocytes because the lipophilic cations (positive charge) move into the mitochondrium due to its high-density and electrochemical transmembrane potential (negative charge) in cardiomyocytes [30] . The myocardial uptake mechanism of these cations is similar to that of Tc-tetrofosmin for SPECT [31] . Therefore, these radiolabeled cation derivatives are potential candidates for developing MIA.
Quaternary ammonium cations as myocardial perfusion PET agent were reported from 2011 [32] [33] [34] . These cations were labeled with 11 C due to drawback of longer half-life of 18 F. A waiting period of four to five half-lives is ideally needed between at rest and stress PET scan to avoid significant interference. However, 18 F-FBnTP is metabolically stable and performs well in healthy and CAD models [30, 46, 48] . However, in vivo characteristics of 18 F-FBnTP, such as higher uptake and longer retention in the heart and more rapid wash out from the liver, need to be improved. 18 [38, [41] [42] [43] [44] . Lipophilicity of the radiotracer could control myocardial selectivity and hepatic clearance. Although little is known about the lipophilicity needed for high myocardial selectivity, the log P value range for cationic radiotracers is 0.5-1.3 to image organs with high mitochondrial density, as a result of their fast membrane-penetration kinetics [50] . The lipophilic interaction between the [ 18 F]FATPs and the lipid layer is attractive because the 18 F-labeled alkyl group increases the lipophilicity [51, 52] . Furthermore, 18 F-labeled TPP derivatives that have different functional groups, such as methyl, methoxy, tert-butyl, dimethyamine-substituted phenyl, and triazole formation, were investigated to assess their performance as MIA for PET [35, 40, 42, 53] . In Vivo Characteristics of 18 
F-Labeled Tetraphenylphosphonium Cation Derivatives
Biodistribution results and microPET images of 18 F-labeled TPP derivatives are shown in Table 1 and Fig. 2 . The lipophilicity, functional group of the triphenylphosphonium core, and structure of 18 F-labeled linker are summarized in Table 2 . Directed 18 F-labeled TPP showed intense cardiac uptake in biodistribution (1.64% ID/g at 5 min after injection; ID, injected dose) and microPET studies (2.3 nCi/cm 3 at 1 min after injection) [45] . A biodistribution study revealed that blood activity changed significantly from 5 to 60 min, reducing from 0.15 to 0.02% ID/g. At 5, 30, and 60 min, lung activity was 0.69, 0.36, and 0.38% ID/g, respectively, whereas liver uptake was 0.34, 0.18, and 0.17% ID/g, respectively. Heart-to-lung ratios at 5, 30, and 60 min were 2, 5, and 4, respectively. The cardiac uptake of 18 F-labeled TPP in rats showed a similar value to that of 99m Tc-tetrofosmin or 99m
Tc-MIBI. The time-activity curve (TAC) generated from PET imaging of rats showed that 18 F-labeled TPP uptake by the heart wall was approximately fourfold higher than blood uptake for 60 min. ]FBnTP showed strongest uptake in the kidney, followed by the heart (12.16% ID/g) and liver (8.09% ID/g), and very 3 TAC revealed that the heart-to-liver ratio and the heart-to-lung ratio were 0.8 ± 0.14 and 0.93 ± 0.07, respectively, at 5 min after injection. 3 images significantly underestimated infarct size soon after tracer injection (0-10 min, P = 0.027), which might be due to the spillover of radioactivity into the left ventricular or right ventricular myocardium [37] . Furthermore, [ 18 F]FATPs showed significantly higher first-pass extraction fraction value than those of [ 13 N]NH 3 in isolated rat hearts perfused by the Langendorff method (flow rates 4, 8, or 16 mL/min, P < 0.05) [6] . The flow rate would be relevant because the MBF of normal rats under isoflurane anesthesia is 4.2 ± 0.9 mL/min [56] .
[ showed high heart uptake (25.24 ± 2.97% ID/g at 5 min after intravenous injection) and the activity was retained for 2 h (28.99 ± 3.54% ID/g at 2 h). However, the liver uptake was decreased dramatically from 14.93 ± 1.46% ID/g (at 5 min) to 0.89 ± 0.29% ID/g (at 120 min). The heart-to-liver, heart-tolung, and heart-to-blood ratios of [ 18 F]FMBTP were 5.04, 5.80, and 32.9, respectively, at 30 min postinjection, and they increased to 32.5, 7.61, and 151.9, respectively, at 120 min postinjection. Furthermore, [ 18 F]mFMBTP showed higher heart uptake (31.02 ± 0.33% ID/g at 5 min postinjection) and better target-to-non target ratios at earlier time points. Both these new radiotracers showed moderate muscle uptake at all time points after injection (6.91 ± 1.04% ID/g for [ 18 showed an excellent image quality in rats for 2 h after intravenous injection. The highest myocardial uptake was reached rapidly at a very early time point after injection and it remained high across all time points to 2 h. With respect to liver uptake, it peaked at 5 min postinjection and rapid clearance was observed. It was even lower than lung uptake after 30 min postinjection. The heart-to-liver ratio increased obviously due to quick clearance from the liver (1.37, 6.62, 12.06, and 18.64 at 5, 30, 60, and 120 min postinjection, respectively). In the case of Beagle dogs, the heart could be clearly seen at 10 min after injection, and heart uptake did not obviously decrease till 2 h. The values for heart-to-liver and heart-tolung uptake ratios were calculated as 1.54 and 6.00 at 10 min after injection, 2.83 and 15.19 at 30 min after injection, 3.98 and 38 at 60 min after injection, and 7.76 and 35.28 at 120 min after injection, respectively. The results of PET imaging in dogs showed a trend similar to biodistribution results in rats and mice. In addition to this, the influence of an additional methoxy group and its different positions on myocardium uptake and pharmacokinetic properties of [ 18 F]FMBTP were examined and reported in 2017 [35] ]FPEGBnTP showed heart uptake of 3.33 ± 0.22% ID/g at 60 min after intravenous injection. In contrast, liver and lung exhibited lower uptakes (0.83 ± 0.02 and 0.81 ± 0.01% ID/g at 60 min, respectively). However, radioactivity uptake in the blood (1.08 ± 0.05% ID/g) was relatively higher than that in the liver and lung 68 Ga-Labeled Myocardial Perfusion Agents 18 F-labeled MPI agents based on the lipophilic cation have been mentioned above; however, these agents depend on the presence of nearby cyclotrons. Recently, 68 Ga (t 1/2 = 68 min) eluted from germanium/gallium (Ge/Ga) generators (parentdaughter combination system) showed high quality with excellent emission properties for clinical PET imaging [57] . The parent nuclide ( 68 Ge) onto a titanium column and the daughter nuclide ( 68 Ga) are simply eluted as 68 GaCl 3 with hydrochloric acid. This generator can be used for more than a year due to the long half-life of the parent nuclide 68 Ge (t 1/2 = days). Furthermore, the short half-life of 68 Ga can be eluted two or three times per day from the generator. Thus, the 68 Ge/ 68 Ga generator is appropriate for experimental or clinical application [58] . Many kinds of synthetic complexes of 68 Ga(III) have been reported as candidate PET tracers for cardiac nuclear imaging [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] . In this review, we have categorized them according to their characteristics, as perfusion imaging agents, MI imaging agents and cardiac metabolic imaging agents, and we have summarized them (Table 3) . 68 Ga-labeled lipophilic cations have been reported as myocardial perfusion agents [59, 60, 62, 73, 74] . Among them, 68 Ga[(4,6-MeO 2 sal) 2 
BAPEN]
+ showed heart-specific accumulation. The myocardial uptake mechanism of 68 Ga-BAPEN is presumably similar to that of 99m Tc-MIBI or [ 18 F]FATPs because radiotracers are lipophilic and have monovalent ions with + 1 charge. However, their labeling procedures are complicated and they need time-consuming operations. Thus, a practical kit was developed to overcome these limitations and to increase usage convenience [58] . In a biodistribution study with balb/c mice, 68 Ga-BAPEN showed strongest uptake in the kidney (52.45 ± 6.25% ID/g), followed by the intestine (18.90 ± 4.05% ID/g), liver (17.73 ± 2.53% ID/g), and heart (11.77 ± 0.83% ID/g) and low uptake in the muscle (1.88 ± 0.43% ID/g) and blood (0.39 ± 0.04% ID/g) at 1 h postinjection. Furthermore, 68 Ga-labeled hexadentate bis(salicylaldimine) chelates (BAPDMEN) derived from BAPEN were reported and they showed promising preclinical results [72] . In rats, the myocardial uptake of the 68 Ga-labeled tracers exceeded that of 99m Tc-MIBI after 1 min postinjection and it showed prolonged retention in the myocardium for 2 h. Tarkia et al. investigated and reported the myocardial uptake and plasma protein binding properties of BAPEN and BAPDMEN derivatives using a pig model [63] . A novel lipophilic monocationic Ga(III)-complex, 67/68 Ga-[3-isopropoxy-ENBDMPI] + , was reported in 2014 [64] . 67 
Ga-[3-isopropoxy-ENBDMPI]
+ showed specific heart uptake (11.98 ± 0.74% ID/g) and low liver uptake (7.44 ± 0.44% ID/g) at 60 min postinjection. They explained that low liver uptake was caused by expression of P-glycoprotein (Pgp) in hepatocytes. The uptake mechanism of lipophilic + in in vitro and in vivo conditions. Finally, they performed a microPET study with Sprague Dawley rats and images showed sustained retention of 68 Ga-[3-isopropoxy-ENBDMPI] + in the heart and rapid clearance from the liver (Fig. 3) . 68 
Ga-Labeled Agents for MI or Cardiac Metabolic Imaging
MI is a dynamic process that begins with coronary occlusion and causes heart muscle damage by decreasing or stopping blood flow to the heart. Because of this, MI is visualized to target biomarkers related to cell damage or healing process, such as inflammation, angiogenesis, and matrix metalloproteinases (MMPs) [65] [66] [67] [68] [69] .
Peptide sequences, asparagine-glycine-arginine (NGR) motif binds to aminopeptidase N (CD13), which is expressed on inflammatory cells [65] . In the myocardium, CD13 is expressed in pathophysiological conditions such as acute MI, where it facilitates inflammatory cell infiltration. Tillmanns J et al. synthesized 68 Ga-NOTA-NGR and compared it with [ 18 F]FDG or 68 Ga-NOTA-arginine-glycineaspartic acid (RGD) motif binds to integrin α v β 3 receptors in myocardial ischemia and reperfusion (MI/R) rat models. The [ 18 F]FDG identified infarcted areas, where increased uptake of 68 Ga-NOTA-NGR was apparent. However, 68 Ga-NOTA-RGD showed higher liver uptake than 68 Ga-NOTA-NGR. Another agent related to the inflammatory process is 68 Ga-pentixafor [67] . Chemokine receptor 4 (CXCR4) is expressed on inflammatory cells after acute MI. CXCR4 belongs to the family of G-protein-coupled receptors and is involved in many kinds of biological processes, such as the entry of HIV-1, the development of metastasis, and several inflammatory conditions. Therefore, the CXCR4 receptor is an attractive biomarker to identify the activated inflammatory cells located in the MI area. 68 Ga-pentixafor is a ligand with high affinity and selectivity to hCXCR4-receptors (IC 50 = 5 nM) and it has been tried in human MI patients. As a result, 68 Ga-pentixafor PET images reveal markedly increased CXCR4 expression in the MI area, indicating an active inflammatory process.
The α v β 3 integrin is expressed on angiogenic vessels and is a potential biomarker for pathological processes. Its expression is upregulated in cancer lesions and metastases as well as in acute MI as part of the infarct healing process [66] . RGD is the principal integrin-binding domain present within extracellular matrix (ECM) proteins such as fibronectin, vitronectin, and fibrinogen. Thus, RGD or synthetic RGD derivatives provide several advantages for targeting integrin for molecular imaging applications [75] . 68 Ga-labeled RGD derivatives, such as 68 Ga-NOTA-RGD and 68 Ga-NODAGA-RGD were evaluated in MI rat and pig models [66, 68] . In PET studies, increased uptake is represented by both radiotracers in the MI area. It means that localized α v β 3 integrin expression in MI may be used as a biomarker to image MI.
MMPs are proteolytic enzymes that play a central role in the degradation of ECM proteins in MI [76, 77] . Especially, the expression of gelatinases MMP-2 and MMP-9 is elevated after myocardial injury. Thus, radioisotope-labeled MMP-2/9 target compound could be used as a PET agent for MI. 68 Galabeled specific MMP-2/9 binding peptide which was identified from the phage display library was evaluated in a MI rat model and it was reported in 2016 [69] . This radiotracer showed accumulation in the damaged rat myocardium after injury; however, its instability and inadequate in vivo characteristics make it unsuitable for further evaluation.
Fatty acids are the major energy source in the myocardium and a change in their metabolism reflects abnormality in the myocardium. Thus, radioisotope-labeled long-chain fatty acids have been investigated as imaging agents since the 1990s [78, 79] . Finally, several kinds of 68 Ga-labeled longchain fatty acids were synthesized and evaluated [70, 71] . The first reported 68 Ga-labeled fatty acids were 68 Ga-NOTAundecanoic acid and 68 Ga-NOTA-dodecanoic acid [70] . These radiotracers showed significant initial uptake in the myocardium; however, significant retention of the activity was found to be associated with blood. Thus, synthetic modification is needed to increase the potential of these radiotracers for myocardial imaging. Another work using 68 Ga-labeled fatty acids aimed to investigate the influence of different chelators of undecanoic acid on cardiac uptake and pharmacokinetics [71] . Jain K et al. synthesized 68 Ga-NODAGAundecanoic acid and 68 Ga-DTPA-undecanoic acid and evaluated their in vivo characteristics. Biodistribution studies showed significant retention of 68 Ga-NODAGA-undecanoic acid in the myocardium. Moreover, rapid washout of 68 Ga-DTPA-undecanoic acid from the liver was observed. However, they suggested amalgamation of the structural features of the two radiotracers for the final design of the 68 Galabeled fatty acid complex that might help to achieve the desired pharmacokinetics for cardiac metabolic imaging.
Conclusion
The development of new radiotracers and/or novel utilization of existing radiotracers are essential steps in cardiac molecular imaging with PET. As described above, many radiotracers are awaiting implementation in the clinical workflow for various cardiac diseases. In parallel with these active research works, clinical efforts should be made to design PET more relevant for patient care.
For example, recent progress in PET in cardiac amyloidosis can provide a good opportunity to promote cardiac PET imaging. PET radiotracers including 18 [80] , while the others were highly specific for immunoglobulin light chain (AL) cardiac amyloidosis [81] [82] [83] . However, indications for PET imaging for a specific subtype have not been established; the interpretation of PET images can be variable due to diverse analytical methods suggested in recent studies. It is mandatory to establish/create comprehensive guidelines on PET imaging in the context of clinical diagnostic work-up of cardiac amyloidosis. The American Society of Nuclear Cardiology published a practical document of practice points for 99m Tc pyrophosphate imaging for TTR cardiac amyloidosis [84] . Patient selection, imaging procedure, interpretation, and quantification methods were comprehensively included, making 99m Tc PYP readily accessible. The same can be done for PET imaging of AL cardiac amyloidosis. It would complete the workflow of molecular imaging, covering the two major subtypes of cardiac amyloidosis.
Cardiac sarcoidosis is also a good disease candidate to promote cardiac PET imaging. 68 Ga-DOTANOC, a neuroendocrine tumor imaging agent, was recently introduced as it showed superior diagnostic accuracy as compared to [ 18 F]FDG [85] . Taking advantage of the accumulation in active inflammation, several 68 Ga-labeled somatostatin analogues are now being investigated in clinical trials. There are ongoing clinical efforts, although they are limited to [ PET findings as one of the diagnostic criteria, and they recommend PET for diagnosis and evaluation of the inflammatory activity in cardiac sarcoidosis [86, 87] . Volumetric parameters are now being applied to diagnosis and prognostic stratification [88, 89] , in addition to the traditional maximal uptake value.
It is also encouraging that a relevant multimodality imaging approach is under investigation for these two disease entities, especially PET-magnetic resonance (MR) [80, 90, 91] . Excellent morphological evidence and tissue characterization are expected to have a synergistic effect with PET. Hybrid PET-MR can be one-stop-shop imaging capable of not only making the diagnosis but also evaluating TTR/AL subtyping or inflammation activity in amyloidosis and sarcoidosis, respectively.
Preclinical and clinical progress can trigger and promote/stimulate the development of each other. There are still challenges and competitors for nuclear cardiology imaging. But cardiac PET has a unique strength based on the infinite potential offered by the development of new radiotracers. 
